EpiBiologics Funding Round

3/22/2023

Venture Equity

$50,000,000

Series A

The company intends to use the funds to expand and validate the platform, advance pipeline of drug candidates, and further build its team. To strengthen their leadership and support their expansion, EpiBiologics also announced the appointment of Shyra Gardai as its incoming Chief Scientific Officer. With over 20 years of scientific and pre-clinical drug development experience across multiple key therapeutic areas, Dr. Gardai has served in roles of increasing responsibilities in the biotechnology industry, including most recently as Vice President of Therapeutic Discovery Research at Seagen.

Private & Independent

Biopharmaceutical

1900 Alameda de las Pulgas 250
San Mateo, CA 94403
USA

Undisclosed

We are a venture backed company with a mission to develop first-in-class and best-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. Protein degradation has the potential to eliminate disease causing proteins that were previously not addressable by classical therapeutic approaches. First generation protein degradation approaches can degrade intracellular proteins but do not address membrane and extracellular proteins, which are approximately 40% of the proteome.